Subject: InMed Pharmaceuticals Strengthens Scientific Advisory Board
PLAIN TEXT:
InMed Pharmaceuticals Strengthens Scientific Advisory Board
Vancouver, BC – March 31, 2015 - InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF), a clinical stage biopha
--->rmaceutical company that specializes in developing safer, more effective cannabis-based therapies, today announced the
---> appointment of Paul C. Anderson, Ph.D., to its Scientific Advisory Board. Dr. Anderson is a pharma industry veteran
--->who brings significant drug discovery and development expertise to InMed.
Dr. Anderson is a synthetic organic chemist by training with more than 30 years of experience in pharmaceutical resear
--->ch and development. Following postdoctoral studies in bioorganic chemistry at the University of Cambridge, Dr. Anderso
--->n began his career in the pharmaceutical industry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelh
--->eim and in more than 20 years with the company, held positions of increasing responsibility in the research organizati
--->on including more than 12 years as head of the Boehringer Ingelheim research centers in Canada and in the United State
--->s. While in Canada, Dr. Anderson and his team introduced several anti-viral drugs into pre-clinical and clinical devel
--->opment, including the first HCV protease inhibitor to be tested in humans. As head of research for Boehringer Ingelhei
--->m in the United States, Dr. Anderson and his team carried out research on autoimmune and cardiovascular diseases, adva
--->ncing several compounds into pre-clinical development. He received his Ph.D. in organic chemistry at the University of
---> Alberta.
Mr. Anderson is also a Consultant for the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN
--->).
“We are delighted to have Paul join our Scientific Advisory Board. Paul brings exceptional medicinal chemistry experti
--->se and vast experience in drug discovery research in several therapeutic areas like CNS, immunology & inflammation and
---> metabolic diseases,” said Craig Schneider, President and CEO of InMed.
In addition, InMed announced the appointment of Dr. Sazzad Hossain to its Board of Directors. Dr. Hossain is the curre
--->nt Chief Scientific Officer of InMed and a co-founder of the company. He developed the “IDP” drug discovery platform a
--->nd is leading all R&D activities of InMed Pharmaceuticals.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through th
--->e research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery syste
--->ms. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental
--->value drivers of the Company.
ON BEHALF OF THE BOARD
InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
Tel: 604.669.7207
Fax: 604.683.2506
info@inmedpharma.com <mailto:info@inmedpharma.com> / www.inmedpharma.com <http://www.inmedpharmaceuticals.com/>
CONTACTS:
Tiberend Strategic Advisors, Inc. <http://www.tiberend.com/>
Joshua Drumm, Ph.D. (Investors)
jdrumm@tiberend.com <mailto:jdrumm@tiberend.com>
212-375-2664
Amy Wheeler (Media)
awheeler@tiberend.com <mailto:awheeler@tiberend.com>
646-362-5750
Forward Looking Statements
This news release contains "forward-looking information" and “forward-looking statements” (collectively, “forward-look
--->ing information”) within the meaning of applicable securities laws. Forward-looking information is based on managemen
--->t's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual res
--->ults to differ materially from those described in the forward-looking statements. Such “forward-looking statements” i
--->nvolve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievem
--->ents to be materially different from those implied by such statements. Known risk factors include, among others: the e
--->xemption may be removed or become no longer applicable; anticipated clinical studies may not be conducted as planned,
--->or at all; and InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not r
--->eturn their expected level of value.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure f
--->ilings with Canadian securities regulatory authorities at www.sedar.com <http://www.sedar.com/>. All forward-looking i
--->nformation herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to rev
--->ise or update any such forward-looking information or to publicly announce the result of any revisions to any of the f
--->orward-looking information contained herein to reflect future results, events or developments, except as required by l
--->aw.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY
--->FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
HTML CONTENT:
<html><head><META http-equiv="Content-Type" content="text/html;charset=utf-8"></head><body><table style="margin-right:
---> 7.35pt; margin-left: 7.35pt;" class="" align="left" border="0" cellpadding="0" cellspacing="0"> <tbody> </tbody></tab
--->le> <p style="text-align: center;" align="center"><strong><span style="font-size: 11pt; font-family: Arial,sans-serif;
--->"><img src="https://irm.ipreo.com/imagehandler.ashx?ID=2211224&ET=2"><br><br>InMed Pharmaceuticals Strengthens Sci
--->entific Advisory Board</span></strong></p> <p style="text-align: justify;" class=""><b><span style="font-size: 11pt; f
--->ont-family: Arial,sans-serif;"> </span></b></p> <p style="text-align: justify;" class=""><b><span style="font-siz
--->e: 11pt; font-family: Arial,sans-serif;">Vancouver, BC – </span></b><b><span style="font-size: 11pt; font-family: Aria
--->l,sans-serif;">March 31</span></b><b><span style="font-size: 11pt; font-family: Arial,sans-serif;">, 2015 -</span></b>
---><span style="font-size: 11pt; font-family: Arial,sans-serif;"> <strong><span style="font-family: Arial,sans-serif;">In
--->Med Pharmaceuticals Inc</span></strong>. (“InMed”) (<b>CSE: IN</b>; </span><b><span style="font-size: 11pt; font-famil
--->y: Arial,sans-serif;">OTCQB: IMLFF</span></b><span style="font-size: 11pt; font-family: Arial,sans-serif;">), a clinic
--->al stage biopharmaceutical company that specializes in developing safer, more effective cannabis-based therapies, toda
--->y </span><span style="font-size: 11pt; font-family: Arial,sans-serif;">announced the </span><span style="color: rgb(34
--->, 34, 34); font-size: 11pt; font-family: Arial,sans-serif;">appointment of Paul C. Anderson, Ph.D., to its Scientific
--->Advisory Board.<span> </span>Dr. Anderson is a pharma industry veteran who brings significant drug discovery and
---> development expertise to InMed.</span></p> <p style="margin-bottom: 15pt; text-align: justify;" class=""><span style=
--->"color: rgb(34, 34, 34); font-size: 11pt; font-family: Arial,sans-serif;">Dr. Anderson is a synthetic organic chemist
--->by training with more than 30 years of experience in pharmaceutical research and development. Following postdoctoral s
--->tudies in bioorganic chemistry at the University of Cambridge, Dr. Anderson began his career in the pharmaceutical ind
--->ustry at Merck Frosst Canada Inc. He subsequently joined Boehringer Ingelheim and in more than 20 years with the compa
--->ny, held positions of increasing responsibility in the research organization including more than 12 years as head of t
--->he Boehringer Ingelheim research centers in Canada and in the United States. While in Canada, Dr. Anderson and his tea
--->m introduced several anti-viral drugs into pre-clinical and clinical development, including the first HCV protease inh
--->ibitor to be tested in humans. As head of research for Boehringer Ingelheim in the United States, Dr. Anderson and his
---> team carried out research on autoimmune and cardiovascular diseases, advancing several compounds into pre-clinical de
--->velopment. He received his Ph.D. in organic chemistry at the University of Alberta.</span></p> <p style="margin-bottom
--->: 15pt; text-align: justify;" class=""><span style="font-size: 11pt; font-family: Arial,sans-serif;">Mr. Anderson is a
--->lso a Consultant for the National Institutes of Health (NIH) Blueprint Neurotherapeutics Network (BPN).</span></p> <p
--->style="margin-bottom: 15pt; text-align: justify;" class=""><span style="color: rgb(34, 34, 34); font-size: 11pt; font-
--->family: Arial,sans-serif;">“We are delighted to have Paul join our Scientific Advisory Board. Paul brings exceptional
--->medicinal chemistry expertise and vast experience in drug discovery research in several therapeutic areas like CNS, </
--->span><span style="font-size: 11pt; font-family: Arial,sans-serif;">immunology & inflammation and metabolic di
--->seases</span><span style="color: rgb(34, 34, 34); font-size: 11pt; font-family: Arial,sans-serif;">,” said Craig Schne
--->ider, President and CEO of InMed.</span></p> <p style="margin-bottom: 15pt; text-align: justify;" class=""><span style
--->="color: black; font-size: 11pt; font-family: Arial,sans-serif;">In addition, InMed announced the appointment of Dr. S
--->azzad Hossain to its Board of Directors. Dr. Hossain is the current Chief Scientific Officer of InMed and a co-founder
---> of the company. He developed the “IDP” drug discovery platform and is leading all R&D activities of InMed Pharmac
--->euticals.</span></p> <p style="text-align: justify;" class=""><span style="font-size: 11pt; font-family: Arial,sans-se
--->rif;"> </span></p> <p style="text-align: justify;" class=""><b><span style="font-size: 11pt; font-family: Arial,s
--->ans-serif;">About InMed </span></b></p> <p style="text-align: justify;" class="Default"><span style="font-size: 11pt;"
--->>InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through t
--->he research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery syst
--->ems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental
---> value drivers of the Company. </span></p> <p style="text-align: justify;"><span style="font-size: 11pt; font-family:
--->Arial,sans-serif;"> </span></p> <p style="text-align: justify;" class=""><b><span style="font-size: 11pt; font-fa
--->mily: Arial,sans-serif;">ON BEHALF OF THE BOARD</span></b></p> <p style="text-align: justify;" class=""><b><span style
--->="font-size: 10.5pt; font-family: Arial,sans-serif;"> </span></b></p> <p style="text-align: justify;" class=""><b
--->><span style="font-size: 10.5pt; font-family: Arial,sans-serif;">InMed Pharmaceuticals Inc.</span></b></p> <p style="m
--->argin-bottom: 0.0001pt;" class=""><span style="font-size: 10.5pt; font-family: Arial,sans-serif;">Craig Schneider <spa
--->n> &n
--->bsp;
---> </span></span></p> <p style="margin-bottom: 0.0001pt;" cl
--->ass=""><span style="font-size: 10.5pt; font-family: Arial,sans-serif;">President and Chief Executive Officer<span>&nbs
--->p; &n
--->bsp;
---> </span></span></p> <p style="margin: 0in -20.15pt 0.0001pt 0in;" class=""><span style="font-size: 10.5pt; font-family
--->: Arial,sans-serif;">Tel:<span> </span>604.669.7207</span></p> <p style="margin: 0in -20.15pt 0.0001pt 0in;" cla
--->ss=""><span style="font-size: 10.5pt; font-family: Arial,sans-serif;">Fax: 604.<i>683.2506</i></span></p> <p style="ma
--->rgin: 0in -20.15pt 0.0001pt 0in;" class=""><a href="mailto:info@inmedpharma.com"><i><span style="font-size: 10.5pt; fo
--->nt-family: Arial,sans-serif;">info@inmedpharma.com</span></i></a><i><span style="font-size: 10.5pt; font-family: Arial
--->,sans-serif;"> / </span></i><a href="http://www.inmedpharmaceuticals.com/"><i><span style="font-size: 10.5pt; font-fam
--->ily: Arial,sans-serif;">www.inmedpharma.com</span></i></a><i><span style="font-size: 10.5pt; font-family: Arial,sans-s
--->erif;"> <span> </span></span></i></p> <p style="margin: 0in -20.15pt 0.0001pt 0in;" class=""><
--->i><span style="font-size: 10.5pt; font-family: Arial,sans-serif;"> </span></i></p> <p class=""><b><span style="co
--->lor: black; font-size: 10pt; font-family: Arial,sans-serif;"> </span></b></p> <p class=""><b><span style="color:
--->black; font-size: 10pt; font-family: Arial,sans-serif;"> </span></b></p> <p class=""><b><span style="color: black
--->; font-size: 10pt; font-family: Arial,sans-serif;">CONTACTS:</span></b></p> <p class=""><i><span style="font-size: 10p
--->t; font-family: Arial,sans-serif;"> </span></i></p> <p class=""><a href="http://www.tiberend.com/"><b><span style
--->="font-size: 10pt; font-family: Arial,sans-serif;">Tiberend Strategic Advisors, Inc.</span></b></a><b><u><span style="
--->font-size: 10pt; font-family: Arial,sans-serif;"> </span></u></b></p> <p class=""><span style="font-size: 10pt; font-f
--->amily: Arial,sans-serif;">Joshua Drumm, Ph.D. (Investors)</span></p> <p class=""><a href="mailto:jdrumm@tiberend.com">
---><span style="font-size: 10pt; font-family: Arial,sans-serif;">jdrumm@tiberend.com</span></a></p> <p class=""><span sty
--->le="font-size: 10pt; font-family: Arial,sans-serif;">212-375-2664</span></p> <p class=""><span style="font-size: 10pt;
---> font-family: Arial,sans-serif;"> </span></p> <p class=""><span style="font-size: 10pt; font-family: Arial,sans-s
--->erif;">Amy Wheeler (Media)</span></p> <p class=""><a href="mailto:awheeler@tiberend.com"><span style="font-size: 10pt;
---> font-family: Arial,sans-serif;">awheeler@tiberend.com</span></a></p> <p class=""><span style="font-size: 10pt; font-f
--->amily: Arial,sans-serif;">646-362-5750</span></p> <p class=""><span style="color: black; font-size: 10pt; font-family:
---> Arial,sans-serif;"> </span></p> <p style="margin: 0in -20.15pt 0.0001pt 0in;" class=""><i><span style="font-size
--->: 10.5pt; font-family: Arial,sans-serif;"> </span></i></p> <p style="text-align: justify;" class=""><span style="
--->color: black; font-size: 8pt; font-family: Arial,sans-serif;"> </span></p> <p style="text-align: justify;" class=
--->""><span style="color: black; font-size: 8pt; font-family: Arial,sans-serif;">Forward Looking Statements</span></p> <p
---> style="text-align: justify;" class=""><span style="color: black; background: none repeat scroll 0% 0% lightgrey; font
--->-size: 8pt; font-family: Arial,sans-serif;"> </span></p> <p style="text-align: justify;" class=""><span style="fo
--->nt-size: 8pt; font-family: Arial,sans-serif;">This news release contains "forward-looking information" and “forward-lo
--->oking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.<span
--->> </span>Forward-looking information is based on management's current expectations and beliefs and is subject to
---> a number of risks and uncertainties that could cause actual results to differ materially from those described in the
--->forward-looking statements.<span> </span>Such “forward-looking statements” involve known and unknown risks, unce
--->rtainties and other factors that may cause actual results, performance or achievements to be materially different from
---> those implied by such statements. Known risk factors include, among others: the exemption may be removed or become no
---> longer applicable; anticipated clinical studies may not be conducted as planned, or at all; and InMed’s proprietary p
--->latform technology, product pipeline and accelerated development pathway may not return their expected level of value.
---></span></p> <p style="text-align: justify;" class=""><span style="font-size: 8pt; font-family: Arial,sans-serif;">&nbs
--->p;</span></p> <p style="text-align: justify;" class=""><span style="font-size: 8pt; font-family: Arial,sans-serif;">A
--->more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure fil
--->ings with Canadian securities regulatory authorities at </span><a href="http://www.sedar.com/"><span style="font-size:
---> 8pt; font-family: Arial,sans-serif;">www.sedar.com</span></a><span style="font-size: 8pt; font-family: Arial,sans-ser
--->if;">. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed dis
--->claims any obligation to revise or update any such forward-looking information or to publicly announce the result of a
--->ny revisions to any of the forward-looking information contained herein to reflect future results, events or developme
--->nts, except as required by law.</span></p> <p style="text-align: justify;" class=""><span style="font-size: 8pt; font-
--->family: Arial,sans-serif;"> </span></p> <p style="text-align: justify;" class=""><span style="font-size: 8pt; fon
--->t-family: Arial,sans-serif;">NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIE
--->WED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.</span></p><img src="https://irm.ipreo.com/B
--->FLink/326421704/BFMailspace.bmp" width="1" height="1" alt="" /></body></html>
© 2024 Canjex Publishing Ltd. All rights reserved.